GLP-1 Weight Loss Statistics: Trial Results at a Glance
Last updated November 7, 2026
Short answer: In the trials behind the FDA labels, adults without diabetes lost an average of 14.9% of body weight on Wegovy 2.4 mg (68 weeks) and 18.8% on the higher 7.2 mg dose (72 weeks), up to 20.9% on Zepbound (72 weeks), 13.6% on the Wegovy tablet (64 weeks), up to 11.1% on the oral pill Foundayo (72 weeks) and 7.4% on Saxenda (56 weeks), versus 2% to 4% on placebo. In the one head-to-head trial, tirzepatide averaged 20.2% and semaglutide 13.7%. About two-thirds of the weight came back within a year of stopping semaglutide. Every number below is taken from a prescribing label or a published trial.
Updated November 7, 2026. This page collects the key published numbers in one place. You can download the average weight-loss table as a CSV, and a suggested citation is at the bottom.
Average weight loss, adults without type 2 diabetes
| Medication | Dose | Average change | Placebo | Length |
|---|---|---|---|---|
| Zepbound (tirzepatide) | 5 mg weekly | -15.0% | -3.1% | 72 weeks |
| Zepbound (tirzepatide) | 10 mg weekly | -19.5% | -3.1% | 72 weeks |
| Zepbound (tirzepatide) | 15 mg weekly | -20.9% | -3.1% | 72 weeks |
| Wegovy (semaglutide) | 2.4 mg weekly | -14.9% | -2.4% | 68 weeks |
| Wegovy (semaglutide), higher dose | 7.2 mg weekly | -18.8% | -3.9% | 72 weeks |
| Wegovy (semaglutide), 2.4 mg arm of the 7.2 mg trial | 2.4 mg weekly | -15.5% | -3.9% | 72 weeks |
| Wegovy (semaglutide) tablet | 25 mg daily | -13.6% | -2.4% | 64 weeks |
| Foundayo (orforglipron) | 5.5 mg daily | -7.4% | -2.1% | 72 weeks |
| Foundayo (orforglipron) | 9 mg daily | -8.3% | -2.1% | 72 weeks |
| Foundayo (orforglipron) | 17.2 mg daily | -11.1% | -2.1% | 72 weeks |
| Saxenda (liraglutide) | 3 mg daily | -7.4% | -3.0% | 56 weeks |
The Wegovy label lets people who tolerate 2.4 mg for at least 4 weeks and need more weight loss move up to a maximum of 7.2 mg weekly. In the 72-week trial of 1,407 adults with obesity, the 7.2 mg dose averaged 3.3 percentage points more weight loss than 2.4 mg.
In the Zepbound and Wegovy trials, everyone, including the placebo groups, also received diet and activity counseling, and the Foundayo label describes its effectiveness as established in combination with a reduced-calorie diet and increased physical activity. The Zepbound trial enrolled 2,539 adults, the Wegovy 2.4 mg trial 1,961, the Wegovy 7.2 mg trial 1,407, the Wegovy tablet trial 307 and the Foundayo trial 3,127. The Saxenda figures are from a 56-week trial of adults with obesity or overweight plus a weight-related condition.
Head to head: tirzepatide vs. semaglutide
SURMOUNT-5 randomly assigned 751 adults with obesity but without type 2 diabetes to tirzepatide or semaglutide at the maximum tolerated dose for 72 weeks, without blinding. Average weight change was -20.2% on tirzepatide and -13.7% on semaglutide. The abstract states that tirzepatide users were more likely to reach losses of at least 10%, 15%, 20% and 25%. See semaglutide vs. tirzepatide.
How many people lose at least 5%, 10%, 15% and 20%
| Medication | At least 5% | At least 10% | At least 15% | At least 20% |
|---|---|---|---|---|
| Wegovy 2.4 mg | 83.5% | 66.1% | 47.9% | 30.2% |
| Wegovy placebo | 31.1% | 12.0% | 4.8% | 1.7% |
| Zepbound 5 mg | 85.1% | 68.5% | 48.0% | 30.0% |
| Zepbound 10 mg | 88.9% | 78.1% | 66.6% | 50.1% |
| Zepbound 15 mg | 90.9% | 83.5% | 70.6% | 56.7% |
| Zepbound placebo | 34.5% | 18.8% | 8.8% | 3.1% |
| Wegovy 7.2 mg (72 weeks) | 88.7% | 79.8% | 63.8% | 45.5% |
| Wegovy 2.4 mg in the same trial | 86.6% | 72.0% | 52.3% | 32.3% |
| Placebo in that trial | 38.3% | 20.3% | 7.5% | 2.8% |
| Wegovy 25 mg tablet (64 weeks) | 76.3% | 59.8% | 47.0% | 27.9% |
| Placebo in the tablet trial | 31.3% | 14.4% | 5.5% | 3.1% |
On Saxenda, 62.3% lost at least 5% (34.4% on placebo) and 33.9% lost more than 10% (15.4% on placebo). So roughly 1 in 6 people on Wegovy and about 1 in 11 on the top Zepbound dose lost less than 5%. See do GLP-1s work?
Results in people with type 2 diabetes
| Medication | Dose | Average change | Placebo | Length |
|---|---|---|---|---|
| Wegovy (semaglutide) | 2.4 mg weekly | -9.6% | -3.4% | 68 weeks |
| Wegovy (semaglutide), higher dose | 7.2 mg weekly | -13.2% | -3.8% | 72 weeks |
| Wegovy (semaglutide), 2.4 mg arm of the 7.2 mg trial | 2.4 mg weekly | -10.4% | -3.8% | 72 weeks |
| Zepbound (tirzepatide) | 10 mg weekly | -12.8% | -3.2% | 72 weeks |
| Zepbound (tirzepatide) | 15 mg weekly | -14.7% | -3.2% | 72 weeks |
| Foundayo (orforglipron) | 5.5 mg daily | -5.1% | -2.5% | 72 weeks |
| Foundayo (orforglipron) | 9 mg daily | -7.0% | -2.5% | 72 weeks |
| Foundayo (orforglipron) | 17.2 mg daily | -9.6% | -2.5% | 72 weeks |
| Saxenda (liraglutide) | 3 mg daily | -5.4% | -1.7% | 56 weeks |
People with type 2 diabetes lost less on average in the same programs. See losing weight with insulin resistance or diabetes.
How fast the weight comes off
- In an analysis of the SURMOUNT-1 trial, the median person who lost at least 5% reached a weight plateau (less than 5% change over 12 weeks) at 24.3 to 36.1 weeks, depending on starting BMI. By week 72, 87.6% to 90.2% had plateaued.
- Higher doses, younger age and female sex were linked to plateauing later. This was a post hoc analysis co-authored by Eli Lilly employees.
See the plateau guide.
What happens after stopping
| Trial | On treatment | After stopping or switching to placebo |
|---|---|---|
| STEP 1 extension (semaglutide, 327 people) | -17.3% at 68 weeks | Regained 11.6 percentage points by week 120, a net loss of 5.6%. Roughly two-thirds of the weight came back. |
| SURMOUNT-4 (tirzepatide, 670 people randomized at week 36) | -20.9% over the first 36 weeks | Switched to placebo: +14.0% from week 36 to 88. Kept taking tirzepatide: -5.5%. |
See what happens when you stop a GLP-1.
Fat versus lean mass
- SURMOUNT-1 body-composition substudy (160 people): weight -21.3%, fat mass -33.9%, lean mass -10.9% on tirzepatide. 74% of the weight lost was fat and 26% was lean mass. The placebo group split 75% and 25%.
- STEP 1 substudy (140 people): weight -15.0% (placebo -3.6%), fat mass -19.3%, lean mass -9.7%.
These were small substudies with limits. See muscle loss on a GLP-1.
Side effects and dropouts
| Side effect | Wegovy | Wegovy placebo | Zepbound 5 / 10 / 15 mg | Zepbound placebo |
|---|---|---|---|---|
| Nausea | 44% | 16% | 25% / 29% / 28% | 8% |
| Diarrhea | 30% | 16% | 19% / 21% / 23% | 8% |
| Vomiting | 24% | 6% | 8% / 11% / 13% | 2% |
| Constipation | 24% | 11% | 17% / 14% / 11% | 5% |
- Wegovy 2.4 mg: 6.8% stopped because of adverse reactions, versus 3.2% on placebo.
- Wegovy 7.2 mg (two 72-week trials, 1,311 adults on 7.2 mg): 5% stopped because of adverse reactions, the same as on 2.4 mg and versus 2% on placebo. Stomach problems accounted for 3% on both doses and 0.3% on placebo. Nausea was reported by 39% on 7.2 mg, 35% on 2.4 mg and 13% on placebo, vomiting by 22%, 16% and 6%, and constipation by 20%, 19% and 8%. Dysesthesia, abnormal skin sensations such as tingling or burning, was reported by 22% on 7.2 mg, 6% on 2.4 mg and none on placebo.
- Zepbound: 1.9%, 3.3% and 4.3% stopped because of stomach side effects at 5, 10 and 15 mg, versus 0.5% on placebo. Overall, 14.3% to 16.4% stopped the study drug, versus 26.4% on placebo.
See nausea and eating tips and GLP-1 side effects.
How this page is compiled
- Medication numbers come from the clinical studies sections of the prescribing labels, using the analysis the label reports (usually all randomized patients). Trial numbers come from the published papers linked above.
- These are group averages from separate trials with different people, doses and lengths. Do not compare rows across trials as if they were head to head. Only SURMOUNT-5 is a direct comparison.
- We update this page when labels change. Spotted an error? Email the address on our about page.
Suggested citation: Health Matters USA. GLP-1 Weight Loss Statistics: Trial Results at a Glance. glp1-calculator.com/learn/glp-1-weight-loss-statistics. Updated November 7, 2026.
Sources
- Wegovy prescribing information (revised 06/2026)
- Zepbound prescribing information (revised 08/2026)
- Foundayo (orforglipron) prescribing information
- Saxenda prescribing information
- Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5, NEJM, 2025)
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension (Diabetes, Obesity and Metabolism, 2022)
- Time to weight plateau with tirzepatide in SURMOUNT-1 and SURMOUNT-4 (Clinical Obesity, 2025)
- Body composition changes with tirzepatide in SURMOUNT-1 (Diabetes, Obesity and Metabolism, 2025)
See what these averages could mean for your own starting and goal weight.
Try the Free GLP-1 CalculatorMedical Disclaimer
This calculator is for educational and informational purposes only and does not provide medical advice, diagnose any condition, recommend or prescribe treatment, or guarantee results. Estimates are based on information you provide and published clinical-trial averages. Individual results can vary significantly.
Estimates are based on average outcomes reported in the STEP 1 (semaglutide) and SURMOUNT-1 (tirzepatide) clinical trials. Individual results can vary significantly and are influenced by factors such as dosage, diet, and adherence.
Do not start, stop, or change any medication based on the results of this calculator. Always consult a qualified healthcare professional regarding medications, treatment options, risks, side effects, and your individual health needs.
